SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel‐Lindau protein ubiquitination and degradation

Rusha Yin,Shuai Liu
DOI: https://doi.org/10.1111/cas.15096
IF: 5.7
2021-08-22
Cancer Science
Abstract:SHANK-associated RH domain interacting protein (SHARPIN) plays an important role in carcinogenesis, as well as inflammation and immunity. Our study explored the effects and underlying mechanisms of SHARPIN in clear cell renal cell carcinoma (ccRCC). By analyzing the TCGA database, we found that upregulated SHARPIN in patients with ccRCC led to a poor prognosis. Then Semiquantitative immunohistochemical analysis of clinical samples was performed and the results suggested the positive association between SHARPIN and hypoxia-induced factor 2α (HIF-2α). Von Hippel-Lindau protein (pVHL) is a tumor suppressor that contributes to degrading HIF-2α. Mechanically, SHARPIN promoted the ubiquitination and proteasomal degradation of pVHL, resulting in the sustained activation of HIF-2α. And the α and β domains of pVHL and ubiquitin-like (UBL) domain of SHARPIN are required for the interaction. The knockdown of SHARPIN effectively inhibited acquired sorafenib resistance in ccRCC cell lines and tumor growth in xenograft models. In conclusion, our work reveals a novel post-translational regulation of SHARPIN on pVHL, indicating that SHARPIN may be a potential target for ccRCC treatment.
oncology
What problem does this paper attempt to address?